Nurexone releases preclinical ExoPTEN imaging results

Executive Summary

• Nurexone Biologic Inc. released new preclinical imaging results demonstrating structural repair in injured spinal cord tissue following treatment with ExoPTEN, showing greater tissue organization and integrity compared to untreated controls.
• The company simultaneously closed a non-brokered private placement of 1,258,072 units at 62 cents per unit, raising approximately $780,000 in gross proceeds for working capital and continued development of ExoPTEN.
• The release highlights the company's progress toward its first-in-human clinical trial, combining these new anatomical findings with previously reported functional data where 100% of animals in a higher-dose group regained motor function.

Key Details

• Preclinical Imaging Results:
  • MRI-Diffusion Tensor Imaging (MRI-DTI) analysis showed that ExoPTEN-treated animals had more organized spinal cord tissue than untreated controls.
  • Fractional Anisotropy (FA): Treated animals showed higher FA values near the injury site, indicating stronger structural integrity and better alignment/preservation of nerve fibers.
  • Mean Diffusivity (MD): Treated animals showed lower MD values, reflecting healthier cellular structure and less disruption from injury.
  • Functional Correlation: These structural findings support previously published functional assessments (July 2025) where 100% of animals in a higher-dose group regained motor function.
• Financing Details:
  • Transaction Type: Non-brokered private placement.
  • Status: Closed, subject to TSX Venture Exchange approval.
  • Units Sold: 1,258,072 units.
  • Price: 62 cents per unit.
  • Gross Proceeds: $780,004.64.
  • Use of Proceeds: Working capital purposes.
  • Investor Participation: Included participation from existing investors who increased their holdings.
• Offering Terms:
  • Warrants: Each unit included one-half of one common share purchase warrant.
  • Warrant Exercise Price: 80 cents per common share.
  • Warrant Term: 36 months, subject to acceleration.
  • Acceleration Clause: If the daily volume-weighted average trading price equals or exceeds $1.70 for 20 consecutive trading days, the company may accelerate the expiry date to 45 days following written notice.
  • Hold Period: Statutory hold period of four months and one day from closing.

Notable Quotes

• "The data from the MRI with diffusion tensor imaging indicates that the injured spinal cords showed greater structural integrity and tissue organization when treated with ExoPTEN in the animal model. Importantly, those structurally preserved spinal cords strengthen the accumulating evidence of ExoPTEN neuroprotective and regeneration-promoting activity following spinal cord injury." — Dr. Kineret Taler, Head of Preclinical Studies
• "This new analytic evidence, together with previously reported functional studies demonstrating recovered walking function in small animals, creates robust, support of the strong preclinical profile of ExoPTEN in spinal cord injury." — Dr. Lior Shaltiel, CEO
• "This limited financing round provides us with additional resources to support our ongoing operations and drive the continued development of ExoPTEN. Notably, the round included participation from existing investors who expressed their confidence in Nurexone by increasing their holdings. As we advance toward our first-in-human studies, we remain committed to prudent financial management and to creating long-term value for our stakeholders." — Eran Ovadya, CFO